Corixa (company)

This article needs additional citations for verification. Please help improve this article by adding citations to reliable sources. Unsourced material may be challenged and removed. Find sources: "Corixa" company – news · newspapers · books · scholar · JSTOR (July 2020) (Learn how and when to remove this message)

This article relies largely or entirely on a single source. Relevant discussion may be found on the talk page. Please help improve this article by introducing citations to additional sources. Find sources: "Corixa" company – news · newspapers · books · scholar · JSTOR (July 2022)

Corixa

Company type	biotechnology/pharmaceutical
Founded	1994 in Seattle, Washington
Defunct	March 31, 2006 (2006-03-31)
Successor	acquired by GlaxoSmithKline
Headquarters	Seattle , Washington
Number of locations	2
Parent	GlaxoSmithKline (United States)

Corixa was a biotechnology/pharmaceutical company based in Seattle, Washington, involved in the development of immunotherapeutics to combat autoimmune diseases, infectious diseases, and cancer. It was founded in 1994. It operated a laboratory and production facility in Hamilton, Montana.

In 2005, the European pharmaceuticals giant GlaxoSmithKline completed the acquisition of Corixa.^[1] GSK had formerly made use of the Corixa's MPL (Monophosphoryl lipid A, a derivative of the lipid A molecule), an adjuvant in some of their vaccines.